|Bid||201.00 x 25000|
|Ask||204.00 x 50000|
|Day's Range||201.00 - 202.00|
|52 Week Range||196.44 - 248.00|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Merck surged to a three-month high Tuesday on strong results for its immuno-oncology and chemotherapy regimen in lung cancer.
Roche's (RHHBY) multiple sclerosis drug Ocrevus gets approval in Europe thereby boosting its neuroscience portfolio. The drug is already approved in the United States.
General Electric Company's (GE) segment GE Healthcare will now help to create a digital platform with Roche to advance medicinal treatments particularly for cancer and critical care patients.
In a relatively slow week, Allergan's (AGN) job cut announcement remained the key highlight while Pfizer's collaboration agreements with Sangamo and Arvinas were also in focus.
Although it's been a relatively slow week, two acquisition deals were announced with Roche (RHHBY) saying it will acquire Ignyta while Mallinckrodt will buy Sucampo.
Roche (RHHBY) is set to acquire Ignyta for $27 per share or a total value of $1.7 billion to strengthen its oncology pipeline further.
Roche has agreed to buy U.S. cancer-therapy company Ignyta for $1.7 billion, the Swiss drugmaker’s latest move to shore up its oncology portfolio as its best-selling treatment faces generic competition....
By purchasing the San Diego-based drug developer Ignyta, Roche will get its hands on an experimental drug that worked dramatically on several kinds of cancer in Phase 1 and 2 clinical trials. After this morning's announcement of a cash deal worth $1.7 billion, or $27 for each share of Ignyta (RXDX), the little firm's shares have jumped 72% to $26.80, while Roche shares (ROG.Switzerland) closed roughly flat at CHF246.30. Initial studies of Ignyta's entrectinib showed it shrinking tumors within weeks among several dozen patients with cancers of the lung, colon and kidney, as well as melanoma. Responses typically lasted two years.
The FDA has approved label expansion of four different drugs from Roche, Exelixis, Pfizer and Bristol-Myers. However, Celgene faced a setback as Revlimid failed in a phase III study.
Roche would pay $27 per share for Ignyta, representing a premium of about 74 percent to the stock's closing price on Thursday, they said. Reuters had reported on Thursday that Ignyta was in advanced talks to sell itself, just three years after going public with a focus on precision drugs and diagnostics. Ignyta will continue its operations in San Diego and will be responsible for the ongoing pivotal study of entrectinib, its most advanced drug.
Roche Holding AG agreed to acquire U.S. biotech Ignyta Inc. for $1.7 billion, following Bayer AG in buying into a class of experimental cancer drugs that home in on a specific mutation across many types ...
Roche's (RHHBY) Perjeta in combination with Herceptin and chemotherapy (the Perjeta-based regimen), gets FDA nod for adjuvant (after surgery) treatment of HER2-positive early breast cancer at high risk of recurrence
The advanced renal cell carcinoma space is back in focus as the FDA approved Cabometyx for treatment-naive patients. Investors will keep an eye on other combination therapies being evaluated for the treatment of advanced RCC,
Roche is touting prospective new drugs from its long-underperforming Swiss-led research unit after years of leaning on its California-based Genentech arm to restock its medicine cabinet. This year, the Swiss drugmaker - the top global spender in pharmaceutical research and development (R&D) - has been talking up several medicines being trialled by Roche Pharma Research & Early Development, or "pRED", as potential stars. Its pRED unit operates independently from Genentech "gRED" research and Roche's Chugai R&D arm in Japan.
Several presentations at the annual meeting of the American Society of Hematology grab headlines in the cancer space.
This week's pharma sector highlights include ASH data, Teva's restructuring announcement and Lilly's (LLY) 2018 outlook.
Roche (RHHBY) announced positive results from a pivotal phase III study, MURANO, evaluating Venclexta plus Rituxan compared to bendamustine plus Rituxan (BR) for the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL).
Roche recently sued Pfizer to block the latter’s biosimilar (generic version) for Herceptin- a cancer biologic that earned $2.5 billion in sales in the U.S. for Roche in 2016. The fight is unlikely to stop there for Roche, as it has a lot more at stake.